The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

HER2DX is a prognostic, predictive assay based on clinical and genomic data. The test integrates clinical information (i.e.

Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that new preclinical data for its lead antibody ...

First study to evaluate HER2DX in a randomized trial focused exclusively on older individuals (aged 70-80 years). HER2DX independently predicts long-term survival outcomes in patients treated ...